Avanza Fonder Ab Neurocrine Biosciences Inc Transaction History
Avanza Fonder Ab
- $3.37 Trillion
- Q4 2024
A detailed history of Avanza Fonder Ab transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Avanza Fonder Ab holds 13,218 shares of NBIX stock, worth $1.88 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
13,218Holding current value
$1.88 Million% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
630Shares Held
93.9MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$2.01 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.42 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$731 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$365 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$265 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...